LIVIVO - Search results -

Search results

Result 1 - 10 of total 40

Search options

Article: RNA Virus Gene Signatures Detected in Patients With Cardiomyopathy After Chemotherapy; A Pilot Study.

Varkoly, Kyle / Tan, Shaoyuan / Beladi, Roxana / Fonseca, David / Zanetti, Isabela Rivabem / Kraberger, Simona / Shah, Chintan / Yaron, Jordan R / Zhang, Liqiang / Juby, Michael / Fath, Ayman / Ambadapadi, Sriram / House, Melanie / Maranian, Paul / Pepine, Carl J / Varsani, Arvind / Moreb, Jan / Schultz-Cherry, Stacey / Lucas, Alexandra R

Frontiers in cardiovascular medicine

2022 Volume 9, Page(s) 821162

Abstract: Background: Viral infections are pervasive and leading causes of myocarditis. Immune-suppression after chemotherapy increases opportunistic infections, but the incidence of virus-induced myocarditis is unknown.: Objective: An unbiased, blinded ... ...

Abstract	Background: Viral infections are pervasive and leading causes of myocarditis. Immune-suppression after chemotherapy increases opportunistic infections, but the incidence of virus-induced myocarditis is unknown. Objective: An unbiased, blinded screening for RNA viruses was performed after chemotherapy with correlation to cardiac function. Methods: High-throughput sequencing of RNA isolated from blood samples was analyzed following chemotherapy for hematological malignancies ( Results: On initial rigorous analysis, low levels of influenza orthomyxovirus and avian paramyxovirus sequences were detectable, but without significant correlation to LVEF (r = 0.208). A secondary broad data mining analysis for virus sequences, without filtering human sequences, detected significant correlations for paramyxovirus with LVEF after chemotherapy (r = 0.592, Conclusions: This is the first report of RNA virus screening in circulating blood and association with changes in cardiac function among patients post chemotherapy, using unbiased, blinded, high-throughput sequencing. Influenza orthomyxovirus, avian paramyxovirus and retrovirus sequences were detectable in patients with reduced LVEF. Further analysis for RNA virus infections in patients with cardiomyopathy after chemotherapy is warranted.
Language	English
Publishing date	2022-03-11
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2022.821162
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Serum Immune Profiling for Early Detection of Cervical Disease.

Ewaisha, Radwa / Panicker, Gitika / Maranian, Paul / Unger, Elizabeth R / Anderson, Karen S

Theranostics

2017 Volume 7, Issue 16, Page(s) 3814–3823

Abstract: Background: The most recent (2012) worldwide estimates from International Agency for Research on Cancer indicate that approximately 528,000 new cases and 270,000 deaths per year are attributed to cervical cancer worldwide. The disease is preventable ... ...

Abstract	Background: The most recent (2012) worldwide estimates from International Agency for Research on Cancer indicate that approximately 528,000 new cases and 270,000 deaths per year are attributed to cervical cancer worldwide. The disease is preventable with HPV vaccination and with early detection and treatment of pre-invasive cervical intraepithelial neoplasia, CIN. Antibodies (Abs) to HPV proteins are under investigation as potential biomarkers for early detection. Methods: To detect circulating HPV-specific IgG Abs, we developed programmable protein arrays (NAPPA) that display the proteomes of two low-risk HPV types (HPV6 and 11) and ten oncogenic high-risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52 and 58). Arrays were probed with sera from women with CIN 0/I (n=78), CIN II/III (n=84), or invasive cervical cancer (ICC, n=83). Results: Abs to any early (E) HPV protein were detected less frequently in women with CIN 0/I (23.7%) than women with CIN II/III (39.0%) and ICC (46.1%, p<0.04). Of the E Abs, anti-E7 Abs were the most frequently detected (6.6%, 19.5%, and 30.3%, respectively). The least frequently detected Abs were E1 and E2-Abs in CIN 0/I (1.3%) and E1-Abs in CIN II/III (1.2%) and ICC (7.9%). HPV16-specific Abs correlated with HPV16 DNA detected in the cervix in 0% of CIN 0/I, 21.2% of CIN II/III, and 45.5% of ICC. A significant number (29 - 73%) of E4, E7, L1, and L2 Abs had cross-reactivity between HPV types. Conclusion: HPV protein arrays provide a valuable high-throughput tool for measuring the breadth, specificity, and heterogeneity of the serologic response to HPV in cervical disease.
MeSH term(s)	Adult ; Antibodies/blood ; Cervical Intraepithelial Neoplasia/blood ; Cervical Intraepithelial Neoplasia/diagnosis ; Cervical Intraepithelial Neoplasia/immunology ; Early Detection of Cancer/methods ; Female ; Human papillomavirus 16/immunology ; Human papillomavirus 18/immunology ; Human papillomavirus 31/immunology ; Humans ; Protein Array Analysis/methods ; Uterine Cervical Neoplasms/blood ; Uterine Cervical Neoplasms/diagnosis ; Uterine Cervical Neoplasms/immunology
Chemical Substances	Antibodies
Language	English
Publishing date	2017
Publishing country	Australia
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	2592097-2
ISSN	1838-7640 ; 1838-7640
ISSN (online)	1838-7640
ISSN	1838-7640
DOI	10.7150/thno.21098
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials.

Gladue, Heather / Maranian, Paul / Paulus, Harold E / Khanna, Dinesh

Arthritis care & research

2012 Volume 65, Issue 4, Page(s) 630–636

Abstract: Objective: Randomized controlled trials (RCTs) in Raynaud's phenomenon (RP) have shown conflicting efficacy data. Also, there is no consensus on the outcome measures that should be used. Our objectives were to assess the reliability of individual core ... ...

Abstract	Objective: Randomized controlled trials (RCTs) in Raynaud's phenomenon (RP) have shown conflicting efficacy data. Also, there is no consensus on the outcome measures that should be used. Our objectives were to assess the reliability of individual core set measures used in 3 RCTs, evaluate the placebo response for individual core set measures, and determine if a composite of individual core set measures will decrease the placebo response, which may improve our ability to see treatment effects in future trials. Methods: We analyzed core set measures from 249 patients in the placebo-treated groups from 3 RCTs. Core set measures analyzed included the Raynaud's Condition Score (RCS); patient and physician assessment of RP; pain, numbness, and tingling during an RP attack; average number of attacks/day; and duration of attacks. Intraclass correlation coefficients (ICCs) were calculated during the run-in period to the RCTs. Results: ICCs of ≥0.70 were observed for the RCS, attack symptoms, and average attacks/day. A high placebo response rate was observed for all individual core measures except the duration of attacks. For the RCS, the placebo response ranged from 56% with ≥10% improvement to 19.5% with ≥60% improvement. In contrast, placebo response rates of 10-20% were observed when several core set measures were combined to develop a composite score. Conclusion: Outcome measures used in RCTs of RP are associated with marked variability. A combination of outcome measures is associated with low placebo responses. Future studies are needed to assess if a composite score will be able to differentiate placebo from an effective agent.
MeSH term(s)	Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Middle Aged ; Outcome Assessment, Health Care/methods ; Raynaud Disease/drug therapy ; Reproducibility of Results ; Retrospective Studies ; Vasodilator Agents/administration & dosage
Chemical Substances	Vasodilator Agents
Language	English
Publishing date	2012-09-13
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural
ZDB-ID	645059-3
ISSN	2151-4658 ; 0893-7524 ; 2151-464X
ISSN (online)	2151-4658
ISSN	0893-7524 ; 2151-464X
DOI	10.1002/acr.21858
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2446: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.A 24: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Bae, Sangmee / Allanore, Yannick / Coustet, Baptiste / Maranian, Paul / Khanna, Dinesh

Clinical and experimental rheumatology

2011 Volume 29, Issue 2 Suppl 65, Page(s) S15–21

Abstract: Objectives: The UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (UCLA-SCTCGIT) 2.0 was developed to assess systemic sclerosis (SSc) associated gastrointestinal tract (GIT) symptoms severity and its impact on patients' well- ... ...

Abstract	Objectives: The UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (UCLA-SCTCGIT) 2.0 was developed to assess systemic sclerosis (SSc) associated gastrointestinal tract (GIT) symptoms severity and its impact on patients' well-being. Our objective was to translate the UCLA-GIT 2.0 from English to French and to evaluate the reliability and validity of the French version. Methods: UCLA-GIT 2.0 was adapted into French using a formal forward-backward translation method and administered to 76 French speaking patients with SSc. The patients also completed the SF-36. We evaluated the internal consistency reliability and construct validity by exploring associations between the UCLA SCTC GIT 2.0 and SF-36 scales. Patients were also classified into two groups based on unintended weight loss within the past 6 months (≥5% vs. <5% of total body weight). Results: Participants were mostly white (90%), female (81%) and had limited SSc (50%). Mean score of the UCLA-GIT 2.0 scales were: 0.35 for faecal soilage, 0.44 for diarrhoea, 0.45 for emotional well-being, 0.48 for both constipation and social functioning, 0.52 for reflux, and 0.95 for distension/bloating. The instrument had acceptable reliability (defined as Cronbach alpha≥0.69) except for the diarrhoea scale (alpha=0.56). The majority of hypothesized correlations were of moderate magnitude (coefficient≥0.30) and were in the appropriate direction. Patients with ≥5% unintended weight loss had worse UCLA-GIT scores in all scales (p<0.05 for distention/bloating scale). Conclusions: The French version of the UCLA-GIT 2.0 has acceptable psychometric properties and can be used in French speaking SSc patients.
MeSH term(s)	Aged ; Diarrhea/etiology ; Fecal Incontinence/etiology ; Female ; France ; Gastrointestinal Tract/physiopathology ; Humans ; Male ; Middle Aged ; Psychometrics ; Quality of Life ; Reproducibility of Results ; Scleroderma, Systemic/complications ; Scleroderma, Systemic/diagnosis ; Scleroderma, Systemic/physiopathology ; Scleroderma, Systemic/psychology ; Severity of Illness Index ; Sickness Impact Profile ; Surveys and Questionnaires/standards ; Translations
Language	English
Publishing date	2011-03
Publishing country	Italy
Document type	Journal Article
ZDB-ID	605886-3
ISSN	1593-098X ; 0392-856X
ISSN (online)	1593-098X
ISSN	0392-856X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2002: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout.

Khanna, Puja P / Perez-Ruiz, Fernando / Maranian, Paul / Khanna, Dinesh

Rheumatology (Oxford, England)

2010 Volume 50, Issue 4, Page(s) 740–745

Abstract: Objective: Short Form-36 (SF-36) is a validated outcome measure to assess health-related quality of life (HRQOL) in patients with gout. We assessed responsiveness to change of SF-36 in patients with gout.: Methods: SF-36 was administered at baseline ... ...

Abstract	Objective: Short Form-36 (SF-36) is a validated outcome measure to assess health-related quality of life (HRQOL) in patients with gout. We assessed responsiveness to change of SF-36 in patients with gout. Methods: SF-36 was administered at baseline and at yearly intervals. We assessed the minimal clinically important differences (MCIDs) at the first and second year. We also assessed the responsiveness to change (effect size) and interpreted it based on Cohen's criteria. We modelled the improvement (defined as ≥MCID) in SF-36 scales and summary scores. Covariates included age, presence of tophi, comorbidities, baseline joint involvement, baseline serum urate, change in serum urate and the number of flares from baseline to 12 months. Results: Of 99 subjects, 96 were male, mean age was 57.1 years, disease duration was 8.2 years and 40.4% had tophi. Ninety-two patients were treated with urate-lowering therapy (ULT) and daily colchicine, and seven were only on colchicine. Baseline mean serum urate level was 8.9 mg/dl and mean number of flares was 4.7 over last year. ULTs were associated with reduction in serum uric acid and number of flares (P < 0.001 for both) over 12 months. Therapy was associated with 22-70% of the patients achieving MCID in SF-36 scores at 12 months. Effect size estimates ranged from negligible to large (SF-36 mental component summary 0.08-bodily pain 1.09). Reduction in flares independently predicted improvements in three SF-36 physical scales (P = 0.001-0.06). Improvement in SF-36 scores was maintained at 2 years. Conclusion: In our real-life observational cohort, chronic urate lowering therapy and colchicine was associated with clinically meaningful improvements in HRQOL at 1 year and then maintained at 2 years. SF-36, especially physical domains and physical component summary, are responsive to change in gout.
MeSH term(s)	Aged ; Chronic Disease ; Cohort Studies ; Colchicine/therapeutic use ; Disability Evaluation ; Dose-Response Relationship, Drug ; Female ; Gout/drug therapy ; Gout/physiopathology ; Gout Suppressants/therapeutic use ; Health Surveys ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Quality of Life ; Treatment Outcome ; Uric Acid/blood
Chemical Substances	Gout Suppressants ; Uric Acid (268B43MJ25) ; Colchicine (SML2Y3J35T)
Language	English
Publishing date	2010-12-08
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	1464822-2
ISSN	1462-0332 ; 1462-0324
ISSN (online)	1462-0332
ISSN	1462-0324
DOI	10.1093/rheumatology/keq346
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 240: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 497: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1–4 Branching, β1–6 Branching, and α2–6 Sialylation in Cancer

Ferdosi, Shadi / Rehder, Douglas S / Maranian, Paul / Castle, Erik P / Ho, Thai H / Pass, Harvey I / Cramer, Daniel W / Anderson, Karen S / Fu, Lei / Cole, David E. C / Le, Tao / Wu, Xifeng / Borges, Chad R

Journal of proteome research. 2018 Jan. 05, v. 17, no. 1

2018

Abstract: Glycans represent a promising but only marginally accessed source of cancer markers. We previously reported the development of a molecularly bottom-up approach to plasma and serum (P/S) glycomics based on glycan linkage analysis that captures features ... ...

Abstract	Glycans represent a promising but only marginally accessed source of cancer markers. We previously reported the development of a molecularly bottom-up approach to plasma and serum (P/S) glycomics based on glycan linkage analysis that captures features such as α2–6 sialylation, β1–6 branching, and core fucosylation as single analytical signals. Based on the behavior of P/S glycans established to date, we hypothesized that the alteration of P/S glycans observed in cancer would be independent of the tissue in which the tumor originated yet exhibit stage dependence that varied little between cancers classified on the basis of tumor origin. Herein, the diagnostic utility of this bottom-up approach as applied to lung cancer patients (n = 127 stage I; n = 20 stage II; n = 81 stage III; and n = 90 stage IV) as well as prostate (n = 40 stage II), serous ovarian (n = 59 stage III), and pancreatic cancer patients (n = 15 rapid autopsy) compared to certifiably healthy individuals (n = 30), nominally healthy individuals (n = 166), and risk-matched controls (n = 300) is reported. Diagnostic performance in lung cancer was stage-dependent, with markers for terminal (total) fucosylation, α2–6 sialylation, β1–4 branching, β1–6 branching, and outer-arm fucosylation most able to differentiate cases from controls. These markers behaved in a similar stage-dependent manner in other types of cancer as well. Notable differences between certifiably healthy individuals and case-matched controls were observed. These markers were not significantly elevated in liver fibrosis. Using a Cox proportional hazards regression model, the marker for α2–6 sialylation was found to predict both progression and survival in lung cancer patients after adjusting for age, gender, smoking status, and stage. The potential mechanistic role of aberrant P/S glycans in cancer progression is discussed.
Keywords	animal ovaries ; blood serum ; disease course ; gender ; glycomics ; liver cirrhosis ; lung neoplasms ; necropsy ; pancreatic neoplasms ; patients ; polysaccharides ; proteome ; regression analysis ; smoking (habit)
Language	English
Dates of publication	2018-0105
Size	p. 543-558.
Publishing place	American Chemical Society
Document type	Article
ZDB-ID	2078618-9
ISSN	1535-3907 ; 1535-3893
ISSN (online)	1535-3907
ISSN	1535-3893
DOI	10.1021/acs.jproteome.7b00672
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 6189: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Satisfaction and access to clinical care in a rheumatology clinic at a large urban medical center.

Agrawal, Harsh / Hay, M Cameron / Volkmann, Elizabeth R / Maranian, Paul / Khanna, Dinesh / Furst, Daniel E

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

2012 Volume 18, Issue 4, Page(s) 209–211

MeSH term(s)	Adult ; Ambulatory Care Facilities/standards ; Ambulatory Care Facilities/statistics & numerical data ; Cohort Studies ; Cross-Sectional Studies ; Female ; Health Services Accessibility/statistics & numerical data ; Humans ; Los Angeles ; Male ; Middle Aged ; Patient Satisfaction/statistics & numerical data ; Pilot Projects ; Rheumatic Diseases/therapy ; Rheumatology/standards ; Rheumatology/statistics & numerical data ; Surveys and Questionnaires ; Urban Health Services/standards ; Urban Health Services/statistics & numerical data
Language	English
Publishing date	2012-06
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	1283266-2
ISSN	1536-7355 ; 1076-1608
ISSN (online)	1536-7355
ISSN	1076-1608
DOI	10.1097/RHU.0b013e318259aa1b
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4815: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial.

Khanna, Puja P / Maranian, Paul / Gregory, Jeff / Khanna, Dinesh

Annals of the rheumatic diseases

2009 Volume 69, Issue 3, Page(s) 588–591

Abstract: Background: The Raynaud's condition score (RCS) is a validated outcome measure for Raynaud's phenomenon (RP).: Objective: To assess the minimally important difference (MID) and patient acceptable symptom state (PASS) for RCS in patients with RP.: ... ...

Abstract	Background: The Raynaud's condition score (RCS) is a validated outcome measure for Raynaud's phenomenon (RP). Objective: To assess the minimally important difference (MID) and patient acceptable symptom state (PASS) for RCS in patients with RP. Subjects: and methods Patients with active RP (n=162) (mean RCS >25 (0-100 visual analogue scale) participated in a placebo-controlled, crossover randomised clinical trial (RCT). Data from the two treatment groups were combined for this analysis. Retrospective and prospective anchors were administered during the RCT. MID groups were defined as the group who reported being somewhat better (anchor #1) and a one-step change from "unbearable" to "very severe", etc (anchor #2). Patients were considered to have achieved PASS if they rated their Raynaud's condition as "very mild" or "mild" at the last study visit. Results: The mean age of participants was 48.9 years and the mean baseline RCS was 46.4 points. The RCS change score for the MID improvement group ranged from -13.9 to -14.3 points and PASS estimate was 34.0 points. Conclusion: The MID and PASS estimates for RCS are 14-15 points for improvement and 34 points, respectively, on a 0-100 scale in a large RCT of patients with active RP. This information can aid in interpreting RCS in future RP trials.
MeSH term(s)	Adolescent ; Adult ; Aged ; Disability Evaluation ; Epidemiologic Methods ; Female ; Humans ; Male ; Middle Aged ; Patient Acceptance of Health Care/psychology ; Raynaud Disease/diagnosis ; Raynaud Disease/drug therapy ; Raynaud Disease/psychology ; Vasodilator Agents/therapeutic use ; Young Adult
Chemical Substances	Vasodilator Agents
Language	English
Publishing date	2009-04-12
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	7090-7
ISSN	1468-2060 ; 0003-4967
ISSN (online)	1468-2060
ISSN	0003-4967
DOI	10.1136/ard.2009.107706
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 167: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Work productivity in scleroderma: analysis from the University of California, Los Angeles scleroderma quality of life study.

Singh, Manjit K / Clements, Philip J / Furst, Daniel E / Maranian, Paul / Khanna, Dinesh

Arthritis care & research

2011 Volume 64, Issue 2, Page(s) 176–183

Abstract: Objective: To examine the productivity of patients with scleroderma (systemic sclerosis [SSc]) both outside of and within the home in a large observational cohort.: Methods: One hundred sixty-two patients completed the Work Productivity Survey. ... ...

Abstract	Objective: To examine the productivity of patients with scleroderma (systemic sclerosis [SSc]) both outside of and within the home in a large observational cohort. Methods: One hundred sixty-two patients completed the Work Productivity Survey. Patients indicated whether or not they were employed outside of the home, how many days per month they missed work (employment or household work) due to SSc, and how many days per month productivity was decreased by ≥50%. Patients also completed other patient-reported outcome measures. We developed binomial regression models to assess the predictors of days missed from work (paid employment or household activities). The covariates included: type of SSc, education, physician and patient global assessments, Health Assessment Questionnaire (HAQ) disability index (DI), Functional Assessment of Chronic Illness Therapy-Fatigue, and Center of Epidemiologic Studies Depression Scale Short Form. Results: The mean age of patients was 51.8 years and 52% had limited cutaneous SSc. Of the 37% of patients employed outside of the home, patients reported missing 2.6 days per month of work and had 2.5 days per month of productivity reduced by half. Of the 102 patients who were not employed, 39.4% were unable to work due to their SSc. When we assessed patients for household activities (n = 162), patients missed an average of 8 days of housework per month and had productivity reduced by an average of 6 days per month. In the regression models, patients with lower education and poor assessment of overall health by a physician were more likely to miss work outside of the home. Patients with limited cutaneous SSc and high HAQ DI scores were more likely to miss work at home. Conclusion: SSc has a major impact on productivity at home and at work. Nearly 40% of patients reported disability due to their SSc.
MeSH term(s)	Absenteeism ; Demography ; Disability Evaluation ; Efficiency ; Employment ; Female ; Health Status ; Health Surveys ; Humans ; Male ; Middle Aged ; Quality of Life ; Scleroderma, Systemic/physiopathology ; Self-Assessment ; Sick Leave
Language	English
Publishing date	2011-11-09
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	645059-3
ISSN	2151-4658 ; 0893-7524 ; 2151-464X
ISSN (online)	2151-4658
ISSN	0893-7524 ; 2151-464X
DOI	10.1002/acr.20676
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2446: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.A 24: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention.

Frech, Tracy M / Khanna, Dinesh / Maranian, Paul / Frech, Edward J / Sawitzke, Allen D / Murtaugh, Maureen A

Clinical and experimental rheumatology

2011 Volume 29, Issue 2 Suppl 65, Page(s) S22–5

Abstract: Objectives: Treatment for gastrointestinal tract (GIT) disease in systemic sclerosis (SSc) is challenging as no immunosuppressive or anti-fibrotic therapy is available with clearly proven efficacy. Probiotics are viable, non-pathogenic microorganisms ... ...

Abstract	Objectives: Treatment for gastrointestinal tract (GIT) disease in systemic sclerosis (SSc) is challenging as no immunosuppressive or anti-fibrotic therapy is available with clearly proven efficacy. Probiotics are viable, non-pathogenic microorganisms that are hypothesized to improve the composition of the intestinal microbiota from a potentially harmful composition to a composition that is beneficial to the host. Our hypothesis is that GIT symptoms in SSc patients with moderate bloating would improve with probiotic implementation. Methods: Ten patients with a moderate-to-severe distention/bloating score (1.25-3.00) on the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0), but otherwise stable organ disease not requiring any medication adjustment were recruited from the University of Utah Scleroderma Center. We compared the GIT 2.0 scores at baseline and after 2 months of use of Align (bifidobacterium infantis; 109 CFU per capsule) or Culturelle (lactobacillus GG; 109 CFU per capsule) using paired t-test and calculated effect size (ES). Results: Significant improvement in total GIT 2.0 score (ES = 0.82), reflux (ES = 0.33), bloating/distention (ES = 1.76), and emotional scales (ES = 0.18) were reported after two months of daily probiotic use. Conclusions: This pilot study suggests probiotics significantly improve the reflux, distention/ bloating, and total GIT scales in SSc patients. As hypothesized, the largest effect was seen in distention/bloating scale. Probiotics may be useful for treatment of SSc-associated distention/ bloating.
MeSH term(s)	Adult ; Aged ; Antifoaming Agents/therapeutic use ; Bifidobacterium/drug effects ; Bifidobacterium/metabolism ; Dietary Supplements ; Female ; Flatulence/microbiology ; Flatulence/pathology ; Flatulence/physiopathology ; Gastrointestinal Diseases/microbiology ; Gastrointestinal Diseases/pathology ; Gastrointestinal Diseases/physiopathology ; Gastrointestinal Tract/microbiology ; Gastrointestinal Tract/pathology ; Gastrointestinal Tract/physiopathology ; Humans ; Lactobacillus/drug effects ; Lactobacillus/metabolism ; Male ; Metagenome/drug effects ; Middle Aged ; Pilot Projects ; Probiotics/therapeutic use ; Scleroderma, Systemic/complications ; Scleroderma, Systemic/physiopathology ; Severity of Illness Index ; Treatment Outcome
Chemical Substances	Antifoaming Agents
Language	English
Publishing date	2011-03
Publishing country	Italy
Document type	Journal Article
ZDB-ID	605886-3
ISSN	1593-098X ; 0392-856X
ISSN (online)	1593-098X
ISSN	0392-856X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2002: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito